SRNE - Sorrento announces subsidiary ADNAB in antibody-drug conjugates push

Sorrento Therapeutics shares jump ([[SRNE]] +16.5%) after it announces the formation of ADNAB, a subsidiary company, that will develop and commercialize a Mayo Clinic-developed technology platform for the manufacture of antibody-drug conjugates ((ADC)) called ADNAB.ADNAB is an immune complex of nanoparticle albumin-bound drug products, which are non-covalently conjugated with tumor-targeting monoclonal antibodies ((mAb’s)).Utilizing Sorrento’s G-MAB library of fully humanized monoclonal antibodies, the ADNAB platform will look to produce a broad portfolio of product candidates targeting liquid and solid tumors, Sorrento said.Sorrento also said that it aims to expand the use of the platform to therapeutic areas beyond Oncology, and said that it has already started work on development of the platform for auto-immune diseases.

For further details see:

Sorrento announces subsidiary ADNAB in antibody-drug conjugates push